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Abstract
Background: Endothelial progenitor cells (EPCs) can migrate to the tumor tissue and enhance the angiogenesis of
hepatocellular carcinoma (HCC); thus, they are associated with a poor prognosis. However, the specific molecular
mechanism underlying the homing of EPCs to the HCC neovasculature remains unrevealed.
Methods: Co-culture experiments of endothelial progenitor cells with HCC cells with modulation of EphA1 were
performed in vitro. Using EPCs as angiogenic promoters by injecting them into HCC xenograft-bearing nude mice
via their tail veins to test homing ability of EPCs changed according to different EphA1 level in HCC xenograft.
Results: In this study, we found that the up-regulation of EphA1 expression in HCC cells could affect not only the
chemotaxis of EPCs to tumor cells and endothelial cells (ECs) but also the tube formation ability of EPCs in a
paracrine fashion. Further, we revealed that the increased expression of EphA1 in HCC cells led to an increased
SDF-1 concentration in the tumor microenvironment, which in turn activated the SDF-1/CXCR4 axis and enhanced
the recruitment of EPCs to HCC. In addition, the EphA1-activated SDF-1 expression and secretion was partially
mediated by the PI3K and mTOR pathways. In vivo experiments demonstrated that blocking EphA1/SDF-1/CXCR4
signaling significantly inhibited the growth of HCC xenografts. Using immunohistochemistry and
immunofluorescence assays, we verified that the inhibition of tumor angiogenesis was at least partially caused by
the decreased number of EPCs homing to tumor tissue.
Conclusions: Our findings indicate that targeting the EphA1/SDF-1 signaling pathway might be a therapeutic
anti-angiogenesis approach for treating HCC.
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Background
Hepatocellular carcinoma (HCC) is the most common
primary liver tumor; it is the second leading cause of
cancer-related death worldwide, and its incidence is
increasing yearly [1]. HCC is often diagnosed at late
stages when only limited therapeutic options are avail-
able; consequently, the survival rate for HCC patients
is dismal. Thus, there is an urgent need to develop
novel therapeutic approaches for advanced HCC. Re-
search has confirmed that angiogenesis is required for
invasive tumor growth and metastasis; thus, angiogen-
esis is an important point in controlling the malignant
progression of tumors, and angiogenesis inhibition
may be a valuable new approach for cancer therapy.
For example, drugs targeting angiogenic pathways,
such as sorafenib, have been proven to have specific
antitumor effects [2]. Clinically, however, sorafenib
treatment has produced only modest survival benefits
in most patients and is not considered curative [3].
Therefore, the development of anti-angiogenic strat-
egies that are more effective for treating HCC remains
a challenging task.
A number of studies suggest that the recruitment of
circulating endothelial progenitor cells (cEPCs) contrib-
utes greatly to tumor neovascularization and that tumor
growth could be inhibited by retarding the incorporation
ability of EPCs [4–7]. Researchers have found that EPCs
can serve as a critical regulator of tumor progression
from micrometastases to macrometastases [8]. Using an
orthotopic liver tumor model, Li et al. confirmed that
the inhibition of the EPC population could suppress liver
tumor metastasis [9]. In addition, our previous study
verified that bone marrow-derived EPCs can home to
the tumor tissue of orthotopic HCC xenografts [10].
Nevertheless, despite the strong evidence supporting the
promotive role of these cells on neovascularization in
HCC, the mechanisms underlying EPCs’ homing and
recruitment to neovessels in HCC remain unclear.
The erythropoietin-producing human hepatocellular car-
cinoma (Eph) receptors, which comprise the largest family
of receptor tyrosine kinases (RTKs), are involved in normal
tissue remodeling and cancer progression, especially in
tumor angiogenesis [11]. Ephrins/Ephs engage in critical
steps of angiogenesis, including juxtacrine cell–cell con-
tacts, cell adhesion to extracellular matrix, and cell migra-
tion [12]. Recent evidence also suggests the important role
of ephrins/Ephs in regulating EPCs’ recruitment and hom-
ing [13, 14]. EphA1, the first identified Eph family member,
is physiologically expressed in epithelial tissues, and its
pathological overexpression has been reported in a variety
of tumors, including gastric cancer [15], liver cancer [16],
prostate cancer [17], and esophageal squamous cell carcin-
oma [18]. In a previous study, an artificial overexpression of
EphA1 in fibroblasts was found to be tumorigenic in nude
mice [19]. Iida et al. reported that EphA1 and its ligand
ephrinA1 were overexpressed in the tumor cells of HCC
and that exogenous ephrinA1-Fc fusion could lead to
increased EphA1 expression and activation of its down-
stream signaling [16]. Our previous study also found that
the targeted suppression of EphA1 expression significantly
inhibited the tumor growth of HCC xenografts, mainly by
suppressing tumor angiogenesis [20]. Although research
suggests a close link between EphA1 and HCC angiogen-
esis, the question of whether the homing of EPCs to HCC
neovasculature is regulated by ephrinA1 and its receptor
EphA1 remains unanswered.
In this study, we used EPCs as angiogenic promoters
by injecting them into HCC xenograft-bearing nude
mice via their tail veins to favor tumor development. By
manipulating the expression of EphA1 in xenografted
tumor tissue and in cultured HCC cells, we observed
that the up-regulation of EphA1 expression in HCC cells
promotes the chemotaxis of EPCs to tumors and endo-
thelial cells through a paracrine mechanism. Further,
both in vivo and in vitro experiments confirmed the
pivotal role of the SDF-1/CXCR4 axis in mediating the
promotive effect of EphA1 on EPCs’ homing to tumor
neovasculature. Our findings indicate that targeting the
EphA1/SDF-1 signaling pathway might provide a thera-
peutic anti-angiogenesis approach to HCC.
Results
Phenotypic and functional characterization of EPCs
derived from peripheral blood
We successfully isolated EPCs from adult peripheral
blood samples (n = 13) and expanded in vitro. EPC
colonies were verified on the 7th day (Additional file 1:
Figure S1a) and were expanded through another 2 weeks
of culture. The cells exhibited a cobblestone-like morph-
ology typical of ECs (Additional file 1: Figure S1a).
Moreover, the cell phenotype was identified using IF assay.
The EPCs were uniformly positive for several endothelial
markers, including CD31, CD133, eNOS, and VEGFR2
(Additional file 1: Figure S1b), and they were able to in-
corporate acetylated-LDL and bind the lectin UEA-1
(Additional file 1: Figure S1c). Importantly, the EPCs were
found to lack the expression of the hematopoietic antigens
CD45 and CD90 (Additional file 1: Figure S1b). Further-
more, Matrigel assays revealed that the EPCs were charac-
terized by their ability to form a network of tube-like
structures (Additional file 1: Figure S1d). These results are
consistent with previous reports [21, 22].
EphA1 regulates EPCs’ chemotaxis and tube formation
potency
EphrinA1 has two native receptors, EphA1 and EphA2.
EphA1 is overexpressed in the tumor tissue in HCC pa-
tients [16, 23]. Therefore, we investigated the role of EphA1
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in EPCs’ chemotaxis and tube formation potency in HCC
cells through manipulating EphA1 gene expression in HLE
cells (EphA1 low expression hepatoma cells) and Huh-7
cells (EphA1 high expression hepatoma cells). EphrinA1-Fc
was used to increase EphA1 expression in HLE cells. The
western blot (WB) assay showed that ephrinA1-Fc recom-
bination protein increased the expression of EphA1 but not
EphA2 (Additional file 2: Figure S2a), consistent with the
results of immunofluorescence staining (Additional file 2:
Figure S2b). The result not only confirmed the success of
the EphA1 expression manipulation, but also ruled out the
possibility that EphA2 is involved as a receptor in
ephrinA1-Fc-activated downstream signaling in HLE cells,
despite a previous finding that ephrinA1-Fc can up-
regulated EphA2 expression and activate its downstream
signaling in endothelial cells [24]. Further, the WB assay
verified that EphA1 siRNA successfully suppressed EphA1
expression in Huh-7 cells (Fig. 1a1). Subsequently, a Trans-
well assay was conducted to investigate the effect of EphA1
upregulation on EPC chemotaxis to HCC cells. The results
demonstrated that the enhanced EphA1 expression in
EphA1-negative HLE cells resulting from ephrinA1-Fc re-
combinant protein increased the chemotaxis of EPCs to
HLE cells, while the decreased EphA1 expression resulting
from EphA1 siRNA transfection in EphA1-positive Huh7
cells had the opposite effect (Fig. 1b). Next, EPC incorpor-
ation into the tubular networks formed by HUVEC was
evaluated. The EPC incorporation assay showed that the
number of Dil-ac-LDL labeled EPCs incorporation into
HUVECs increased after treatment with conditional
medium (CM) from the EphA1 high expression HCC cells
(HLE cells treated with ephrinA1-Fc recombinant protein
or Huh-7 cells transfected with EphA1 scrRNA) compared
to treatment with CM from the EphA1 low expression
HCC cells (HLE cells treated with IgG-Fc recombinant pro-
tein or Huh-7 cells transfected with EphA1 siRNA)
(Fig. 1a2, a3). Furthermore, wound healing and tube forma-
tion assays were conducted to investigate whether EphA1
up-regulation in HCC cells promotes EPCs’ potency for
physiological angiogenesis. The results demonstrated that
the migration ability of EPCs remarkably increased after
treatment with conditioned medium from EphA1-negative
HLE cells stimulated with recombinant human ephrinA1-
Fc and decreased after treatment with conditioned medium
from EphA1 siRNA-transfected EphA1-positive Huh7 cells
(Fig. 1c). The same tendency was found in the tube forma-
tion assay (Fig. 1d). These results indicate that the increased
expression of EphA1 in HCC cells promotes the chemotac-
tic and tube formation abilities of EPCs in the tumor
microenvironment.
EphA1 activates SDF-1/CXCR4 signaling in HCC
Chemokines have been verified as the key factors mediat-
ing EPCs’ homing for tumor neovascularization [25]. To
verify whether EphA1 can increase chemokine expression
and secretion in HCC cells, we detected 10 chemokines
that are known to be associated with HCC [26–35] and
designed specific primers for PCR assays (Table 1). Using
qPCR and ELISA, we found that among all of the detected
chemokines, the up-regulation of EphA1 expression in
ephrinA1-Fc-stimulated HLE cells resulted in the most
significant increase in SDF-1 mRNA expression in cells
(Fig. 2a) and protein secretion into the culture medium
(Fig. 2c). Consistently, the inhibition of EphA1 expression
by EphA1 siRNA in EphA1-positive Huh7 cells led to de-
creased mRNA expression (Fig. 2b) and protein secretion
(Fig. 2c) in SDF-1. The findings from immunofluorescence
staining with SDF-1 (green) and DAPI (blue) were consist-
ent with those of the qPCR assay (Fig. 2d).
To further verify whether SDF-1/CXCR4 signaling is the
key contributor to EPCs’ homing process in response to the
EphA1 level change in HCC cells, we performed an IP
assay using the lysates from EPCs after they were co-
cultured with IgG-Fc- or ephrinA1-Fc-stimulated HLE cells
and the SDF-1 antibody, followed by a WB assay of the
immunoprecipitated eluate (IP eluate) for CXCR4. The re-
sults demonstrated that the IP eluate from the cells with in-
creased SDF-1 expression had a remarkably higher CXCR4
level, suggesting that SDF-1 and CXCR4 interact with each
other (Fig. 3a). In addition, using immunofluorescence (IF),
we verified that compared with the control group, EPCs
co-cultured with ephrinA1-Fc-activated HLE cells showed
significant SDF-1 and CXCR4 co-expression (Fig. 3b).
To rule out the possibility of EphA2 involvement, we
successfully constructed EphA2 siRNA to knock down the
EphA2 gene, as evidenced by the fact that EphA2 siRNA-
transfected Huh-7 cells showed a significantly lower
EphA2 mRNA expression level compared with EphA2
scrRNA-transfected Huh-7 cells (Additional file 2: Figure
S2c). Subsequently, a qPCR assay revealed that EphA2
siRNA-transfected Huh-7 cells did not exhibit any signifi-
cant changes in the mRNA expression levels of any of the
detected chemokines (Additional file 2: Figure S2d).
The above results indicate that EphA1 is the key receptor
responding to ephrinA1-Fc stimulation in HLE cells and
that the up-regulation of EphA1 expression can activate
SDF-1/CXCR4 signaling in the tumor microenvironment.
SDF-1 inhibition suppresses the EphA1-induced chemo-
taxis and tube formation ability of EPCs
To investigate whether SDF-1 inhibition blocks the EphA1-
activated chemotaxis and tube formation ability of EPCs,
we transfected SDF-1 siRNA into ephrinA1-Fc-stimulated
HLE cells with an up-regulated EphA1 expression and used
scrambled siRNA as a control. WB showed decreased SDF-
1 protein expression and secretion (Fig. 4a, b), confirming
the success of the SDF-1 gene knockdown. The Transwell
experiment demonstrated that compared with the control
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scrambled RNA, the SDF-1siRNA knockdown of HLE cells
with an activated EphA1 expression led to a significant
decrease in EPC chemotaxis (Fig. 4c1). In addition, after
treatment with conditioned medium from SDF-1 knock-
down ephrinA1-Fc-activated HLE cells, EPCs’ abilities to
migrate (Fig. 4c2), form a tubular structure (Fig. 4c3), and
incorporate into mature EC populations (Fig. 4c4) were all
suppressed compared with the SDF-1 scrambled RNA
group. These results suggest that targeting SDF-1 might
decrease the EphA1-induced chemotaxis and tube forma-
tion ability of EPCs in the tumor microenvironment.
EphA1 promotes SDF-1 expression in HCC cells through
the Akt and mTOR pathway
To identify the pathway involved in the EphA1-activated
expression and secretion of SDF-1 in HCC cells, we first
examined the protein expression of three EphA1 down-
stream signaling molecules, ERK, Akt and mTOR. WB
Fig. 1 EphA1 regulates EPC proangiogenic potency in a paracrine fashion in vitro. a A1: WB assay showing the EphA1 protein expression in HCC
cells. A2: EPC incorporation into HUVECs, EPC’s uptake of DiI-ac-LDL (red) together with HUVEC tube formation (blue). A3: EPC incorporation assay
analysis data (**P< 0.01). The data are expressed as the means ± SD of three independent experiments. b Boyden chamber staining of EPCs’ chemotaxis to
HCC cells with different EphA1 levels, Asterisks indicate significant differences (**P< 0.01, ***P< 0.001) with respect to the corresponding control. The data
are expressed as the mean ± SD of three independent experiments. c: EPC migration. d EPC tube formation. The migration and tube formation of EPCs
were measured after treatment with conditioned medium from HCC cells with different EphA1 levels. The data are expressed as the mean ± SD of three
independent experiments. Asterisks indicate significant differences (**P< 0.01, ***P< 0.001) with respect to the corresponding control
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results revealed that the active EphA1 in ephrinA1-Fc-
stimulated HLE cells increased the protein expressions of
phosphor-Akt and phosphor-mTOR; however, no differ-
ence in the protein level of phosphor-ERK was observed.
Consistently, the knockdown of EphA1 expression by
EphA1 siRNA in EphA1-positive Huh7 cells exhibited the
opposite changes (Fig. 5a, b). Next, using LY294002 (an in-
hibitor of the Akt signaling pathway) and rapamycin (an in-
hibitor of the mTOR signaling pathway), we found that
blocking the Akt and mTOR pathway in HCC cells de-
creased EphA1-activated SDF-1 expression (Fig. 5c). The
findings from immunofluorescence staining with EphA1
Table 1 The primer sequences of Chemokines used in this article











Fig. 2 Up-regulated EphA1 expression in HCC cells promotes SDF-1 expression and secretion. A-B. Chemokine mRNA expression profile determined
with qRT-PCR. The data represent the mean ± SD of three independent experiments. a HLE cells: The result of ephrinA1-Fc-activated HLE cells is
normalized to the expression in the IgG-Fc-activated HLE cells for each chemokine. The red bar represents the relative SDF-1 mRNA expression level in
the ephrinA1-Fc-activated HLE cells. Asterisks indicate significant differences (***P < 0.001) with respect to the IgG-Fc-activated HLE cells. B. Huh-7 cells
with different EphA1 expression levels: The result is normalized to the expression in Huh-7 cells transfected with EphA1 scrRNA for each chemokine.
The red bar represents the relative SDF-1 mRNA expression level in Huh-7 cells transfected with EphA1 siRNA. Asterisks indicate significant differences
(**P < 0.01) with respect to the Huh-7 cells transfected with EphA1 scrRNA. b SDF-1 protein concentration, evaluated with ELISA, in conditioned
medium from HCC cells with different EphA1 levels. The data represent the mean ± SD of three independent experiments. Asterisks indicate significant
differences (**P < 0.01). c IF staining of SDF-1 (green) and DAPI (blue) in HCC cells (top panel: HLE cells; bottom panel: Huh-7 cells). Images were
obtained using a confocal laser scanning microscope. Magnification: × 400; scale bar, 20 μm
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(green), SDF-1 (red), and DAPI (blue) were consistent with
those of the WB assay (Fig. 5d). These results suggest that
the Akt and mTOR pathway mediates the enhancement of
SDF-1 expression and secretion by EphA1 in HCC cells.
EphA1 promotes EPCs’ homing for neovascularization of
HCC xenografts
To further clarify whether targeting SDF-1 can suppress
EphA1-induced HCC growth and EPCs’ homing process,
we established HLE cell xenograft models with different
EphA1 levels in mice, which were then injected with EPCs
through the tail vein on the post-xenograft 14th day. After
36 days, the tumors containing HLE cells with activated
EphA1 had a significantly greater volume than the tumors
containing HLE cells stimulated with control IgG-Fc
(Fig. 6a). In addition, compared with SDF-1 scrambled
RNA, the SDF-1 siRNA-treated HLE cells with activated
EphA1 expression showed remarkably smaller resulting tu-
mors (Fig. 6b, c1), suggesting a pivotal role of SDF-1 in
EphA1-enhanced tumor growth. Next, we investigated the
effect of targeting SDF-1 on EphA1-induced HCC angio-
genesis by comparing the microvascular density (MVD) of
the xenografts of mice injected with SDF-1 siRNA-treated
HLE cells and those treated with SDF-1 scrambled RNA-
treated HLE cells. MVD was determined based on the IHC
staining of tumor tissue for CD31. The results indicate that
compared with the scrambled RNA control group, SDF-1
knockdown by siRNA significantly inhibited MVD in the
tumors containing HLE cells with activated EphA1 expres-
sion (Fig. 6c2, d1). Next, we further verified the role of
SDF-1 in the EphA1-promoted recruitment of EPCs to
HCC for vascularization as a key downstream molecule.
Dil-ac-LDL labeling was used to track the homing of EPCs
to the tumors’ CD31-positive vasculature (Fig. 6c3), and the
number of EPCs per microscope field of tumor tissue was
counted. The results revealed that compared with the
SDF-1 scrambled RNA-transfected cells with activated
EphA1 expression, the HCC xenografts derived from
SDF-1 siRNA-knockdown HLE cells had a smaller num-
ber of EPC cells homing to the tumor vasculature
(Fig. 6d2). These results indicate that the activation of
EphA1 expression promoted angiogenesis in HCC and
that targeting SDF-1 might be an effective tool for inhibit-
ing EphA1-induced HCC angiogenesis and EPC recruit-
ment. The working model of how the EphA1-activated
SDF-1/CXCR4 signaling promote EPCs’ homing to HCC
neovascularization was presented (Fig. 7).
Discussion
By constructing an orthotopic tumor in rat livers and
injecting EPCs through the tail vein after a xenograft tumor
developed, we preliminarily confirmed that EPCs can spe-
cifically chemotax to HCC tumor tissue [20]. However, the
definitive molecular mechanism underlying this homing
process remains to be clarified. In the present study, we ob-
served that up-regulated EphA1 expression in HCC cells in-
creased SDF-1 expression and secretion in the tumor
microenvironment, which in turn not only promoted the
chemotaxis, tube formation and migration ability of EPCs
but also enhanced tumor growth and microvascular density.
Importantly, in vivo experiments revealed that an increased
number of EPCs homed to neovessels in HCC. Moreover,
this study found that EphA1-activated SDF-1 expression and
secretion was mediated by Akt and mTOR pathway.
Previous studies have reported an elevated expression
level of EphA1 and its analogue, EphA2, in the tumor tissue
of HCC patients [16, 36]. Our previous study also showed
that the targeted inhibition of EphA1 could inhibit tumor
growth and angiogenesis in HCC [20]. In this study, we
used ephrinA1 fusion protein and verified that ephrinA1
can activate EphA1 but not EphA2 receptors in an EphA1-
negative HCC cell line of HLE cells (Additional file 2:
Figure S2), which was similar to Iida’s findings [16].
Fig. 3 EphA1 increases the binding of SDF-1 to CXCR4 in EPCs. a
Cell lysates from EPCs co-cultured with IgG-Fc-activated (Lane 1) or
ephrinA1-Fc-activated HLE cells (Lane 2) were used for co-IP using
anti-SDF-1 antibodies. WB was performed using antibodies against
CXCR4, with β-actin as a control for protein loading. The histogram
on the right shows the semi-quantification results of WB. The data
represent the mean ± SD of three independent experiments. The results
show that the activation of EphA1 leads to an increased pull-down of
CXCR4 in EPCs. b IF staining of EPCs after co-culturing with IgG-Fc-
activated (top panel) or ephrinA1-Fc-activated HLE cells (bottom panel)
using anti-CXCR4 antibody (green fluorescence), anti-SDF-1 antibody (red
fluorescence), and DAPI (blue fluorescence). Yellow fluorescence in the
merged images indicates the co-expression of SDF-1 and CXCR4 in EPCs
after co-culturing with HLE cells activated by IgG-Fc or ephrinA1-Fc.
Images were obtained using a confocal laser scanning microscope.
Magnification: × 400; scale bar, 10 μm
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Tumor vasculatures develop mainly through angiogenesis
via endothelial sprouting from the existing vessels, and this
sprouting process is based on the recruitment, proliferation
and tube formation of EPCs [37, 38]. The homing of cEPCs
to the tumor participates in the angiogenesis process by
differentiating and incorporating into the EC populations of
the neovessels of HCC or into the tumors themselves. A
number of studies have revealed that ephrin/Eph family
members can regulate the recruitment and homing of EPCs
to tumors. For example, Foubert et al. found that the inhib-
ition of EphB4 activity in EPCs significantly reduced EPC-
induced angiogenesis [13] and further revealed that EPCs
pretreated with ephrin-B2 have a proangiogenic potential
for therapeutic neovascularization [23]. Similarly, Salvucci
et al. [39] reported that the EphB2/ephrinB2 signaling path-
way could promote EPC chemotaxis and accelerate vascu-
lar branching and remodeling. The ephrinA1/EphA1
pathway was also found to be involved in the malignant
biological behavior of HCC tumor cells [16]. However, the
relationship between the ephrinA1/EphA1 pathway and
EPC homing ability in HCC remains to be determined. In
this study, the Boyden chamber assays showed that the
chemotaxis of EPCs to the ECs and tumor cells was signifi-
cantly enhanced in the conditioned medium from HLE cell
cultures with activated EphA1. The results of these and
other assays, allowed us to show for the first time that the
ephrinA1/EphA1 pathway activated in HCC can promote
EPCs homing process in a paracrine fashion.
Recent studies have found that in addition to the EPCs’
physical contribution to newly formed vessels, the en-
hanced secretion of chemokines might be a supportive
mechanism underlying the homing process of EPCs to
tumor neovasculature [25]. As one of the most important
chemokines involved in the angiogenesis of HCC [30],
SDF-1 mediates the homing of cEPCs to neovessels by
binding to the receptor CXCR4 on EPCs [40]. In this study,
the activation of the ephrinA1/EphA1 signaling pathway in
HCC cells led to an elevated SDF-1 protein level in the
HCC tumor microenvironment. Moreover, targeting SDF-1
with siRNA suppressed the ephrinA1/EphA1-enhanced
Fig. 4 The effect of EphA1 on HCC angiogenesis is SDF-1 dependent in vitro. a WB of SDF-1 in ephrinA1-Fc-activated HLE cells transfected with SDF-1
scrRNA or SDF-1 siRNA, with β-actin as a control for protein loading. b The SDF-1 protein concentration in conditioned medium from ephrinA1-Fc-
activated HLE cells transfected with SDF-1 scrRNA or SDF-1 siRNA, evaluated with ELISA. Asterisks indicate significant differences (**P< 0.01), and “ns”
indicates an insignificant difference. c The abilities of EPCs to incorporate into the HUVECs (C1), migrate (C2), chemotax to HLE cells (C3), and form tubular
structures (C4) were measured after treatment with conditioned medium from ephrinA1-Fc-activated HLE cells transfected with SDF-1 scrRNA or SDF-1
siRNA. The data represent the mean ± SD of three independent experiments. Asterisks indicate significant differences (**P< 0.01; ***P< 0.001)
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potential of EPCs to migrate to the tumor cells. In in vivo
experiments, SDF-1 blockage reversed the promotive effect
of ephrinA1-Fc against tumor growth and angiogenesis in
the nude mouse HCC xenograft model. Meanwhile, the
number of EPCs in the tumor neovessels drastically
decreased. Therefore, we believe that the reduction of EPC
recruitment might be a major contributor to the change in
tumor angiogenesis resulting from SDF-1/CXCR4 axis
blockage. In HCC, previous studies have verified that SDF-
1/CXCR4 axis could be up-regulated by TIMP-1 [41] and
Fig. 5 EphA1 increases SDF-1 expression via activation of the Akt and mTOR pathways. a WB assay of the EphA1 downstream signaling molecules
ERK, AKT and mTOR, expressed in untreated and treated HLE cells as well as Huh-7 cells with manipulated EphA1 levels, with β-actin as a control
or protein loading. b Histograms show the relative (Rel) protein expression results from WB, which were normalized to the expression level in
untreated cells. The data represent the mean ± SD of three independent experiments. Asterisks indicate significant differences (**P < 0.01; ***P <
0.001), and “ns” indicates an insignificant difference. c The WB assay of SDF-1 in IgG-Fc- or ephrinA1-Fc-activated HLE cells after the respective
blockage of the Akt and mTOR pathways with the corresponding specific inhibitors LY294002 (2 ng/ml) and rapamycin (2 ng/ml). Β-actin served
as a control for protein loading. The data represent the mean ± SD of three independent experiments. Asterisks indicate significant differences
(**P < 0.01) d Double IF staining of SDF-1 (green) and EphA1 (blue). Images were obtained using a confocal laser scanning microscope. The results
show that SDF-1 expression decreases after the blockage of the Akt and mTOR pathways with their respective specific inhibitors, LY294002 (2 ng/ml)
and rapamycin (2 ng/ml). Magnification: × 400; scale bar: 10 μm
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urokinase [42]. Interestingly, tacrolimus, an immunosup-
pressor, can also promote HCC by activating SDF-1/
CXCR4 axis [43]. Here, for the first time, we observed that
the SDF-1/CXCR4 axis can be activated by the increased
expression of EphA1 in HCC cells in the tumor microenvir-
onment. This finding is similar to a previous report that
EphB2 and EphB4 might possess the ability to up-regulate
the expression of SDF-1 [39]. In addition to SDF-1, other
chemokines, such as CXCL16/CXCR6 [44], CXCL10/
CXCR3 [28], and CCL5/CCR5 [45], might play a regulatory
role in EPCs mobilization and recruitment. However, we
did not notice any significant gene expression changes in
these chemokines in HCC cells in response to EphA1
activation.
The ephrin/Eph family executes various biological func-
tions by regulating multiple downstream pathways [11]. For
example, ephrinA1-induced activation of EphA2 stimulates
the MAP/ERK kinase signaling cascade [46], EphB4 recep-
tor signaling mediates endothelial cell migration and prolif-
eration via the PI3K/Akt pathway [47], and the mTOR
pathway is a crucial mediator of EphA signaling in neurons
[48]. Because mTOR is known to be an important
Fig. 6 Targeted SDF-1 inhibition suppresses EphA1-mediated HCC angiogenesis and EPCs’ homing process in vivo. HLE cells were injected in 6-week-old
nude nu/nu (CD-1) mice to develop tumors. When a tumor mass was evident (14 days), Dil-ac-LDL-labeled EPCs were intravenously injected into the mice
through the tail vein, as described in the Methods section. a Comparison of tumor growth between the IgG-Fc groups and ephrinA1-Fc groups (top panel)
and the EphA1 expression levels in these two groups (bottom panel). b Comparison of tumor growth between the ephrinA1-Fc + SDF-1 scrRNA group and
ephrinA1-Fc + SDF-1 siRNA group (top panel) the SDF-1 expression in these two groups (bottom panel): The tumor growth curves were obtained by
measuring the tumor volume every 3 days. c Top: Representative photograph of the xenograft of HLE cells treated with ephrinA1-Fc to
activate EphA1 expression and transfected with SDF-1 siRNA (top panel) or scrRNA (bottom panel); middle: IHC staining images of tumors from
each group using anti-CD31 antibody; bottom: high-magnification cross-section images of one single vessel selected from the IHC image of
the ephrinA1-Fc + SDF-1 siRNA group (indicated by the red box in the image in the middle panel). As the images indicate, EPCs labeled 1DiI
(red) also express the EC marker CD31 (green) and are mainly located in the tumor vasculature (×200; scale bar, 50 μm). d Top: Microvascular
density of HLE cells with ephrinA1-Fc-activated EphA1 expression transfected with SDF-1 siRNA (red bar) or scrRNA (black bar) in the
xenografts; Bottom: Number of EPCs homing to the tumor vasculature of HLE cells with ephrinA1-Fc-activated EphA1 expression transfected
with SDF-1 siRNA (red bar) or scrRNA (black bar) in the xenografts
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downstream molecule of Akt, we hypothesized that the
Akt/mTOR pathway can be activated by ephrinA1/EphA1
and thus become involved in the homing process of EPCs
to HCC. Using specific chemical pathway inhibitors to in-
vestigate the role of the Akt/mTOR pathway, we found that
the blockage of the PI3K/Akt and mTOR pathways remark-
ably suppressed EphA1-activated SDF-1 expression and
secretion, suggesting that the Akt/mTOR pathway mediates
the up-regulation of SDF-1 by EphA1. Our results were in
accordance with a previous study that observed the involve-
ment of the ephrinA1/EphA1-activated PI3K/Akt pathway
in chemokine-mediated T lymphocyte migration [49].
In summary, the most significant and novel finding of
this study is that the activation of the ephrinA1/EphA1
pathway in HCC cells can significantly increase the ex-
pression and secretion of SDF-1 in the tumor micro-
environment, thus promoting tumor angiogenesis by
enhancing the homing and tube formation abilities of
EPCs in a paracrine fashion. The homing of EPCs in
tumor angiogenesis is a multi-step process involving the
interactions and mutual influence of multiple factors
and complicated signal transduction pathways. Our
identification of the signal pathway and its function in
HCC progression could be breakthrough that sheds new
light on tumor anti-angiogenesis therapy.
Conclusions
Our findings indicate that ephrinA1/EphA1 pathway ac-
tivation in HCC cells can promote tumor angiogenesis
by enhancing the homing and tube formation abilities of
EPCs in a paracrine fashion, and targeting the EphA1/
SDF-1 signaling pathway might be a therapeutic anti-
angiogenesis approach for treating HCC.
Methods
Cell culture
After EPCs were isolated from peripheral blood, they were
expanded ex vivo, as previously described [50]. Early pas-
sage EPCs (passage 2) were seeded in flasks pre-coated
with type I rat tail collagen and cultured in complete
EGM-2 medium (Lonza, NJ, USA). Human umbilical vein
endothelial cells (HUVECs) were isolated from human
umbilical venous blood via collagenase digestion and then
cultured in complete EGM-2 medium in flasks coated
with type I collagen. All cultures were maintained in a hu-
midified incubator at 37 °C in an atmosphere containing
5 % CO2. Passage 2 EPCs and passage 2 HUVECs were
used in the related experiments in this study. In addition,
two human hepatoma cell lines, HLE (EphA1-negative)
and Huh-7 (EphA1-positive) were obtained from the Japan
Health Science Research Resources Bank (HSRRB, Osaka,
Japan). HLE was cultured in complete MEM medium con-
taining 10 % fetal bovine serum (FBS; Gibco, NY, USA).
The Huh-7 was cultured in 10 % FBS-containing Dulbec-
co’s Modified Eagle’s Medium (DMEM).
Animal studies
The Wenzhou Medical University Committee for the Use
and Care of Animals approved all animal experiment pro-
cedures prior to the study. Forty-eight 6- to 7-week-old
male C57BL/6 nude mice (Center for Laboratory Animals,
Wenzhou Medical University, Wenzhou, China) were
Fig. 7 Working model of how the EphA1-activated SDF-1/CXCR4 signaling promotes EPCs’ homing to HCC neovascularization. a In the HCC
tumor mass, cEPCs incorporate into the EC layers and tumor vessels (angiogenesis) or migrate to non-vascularized tumor sites to facilitate
the initial establishment of the tumorous endothelium, contributing to angiogenesis by providing structural support for nascent vessels
(vasculogenesis). b In the tumor microenvironment, ephrinA1/Fc-forced expression of EphA1 activates its downstream signaling molecular
AKT and mTOR and then increases the expression and secretion of SDF-1 to the tumor microenvironment. Secreted SDF-1 in turn binds
with its receptor CXCR4 on the EPC cell membrane and contributes to the increased angiogenic potency of EPCs and their ability to
chemotax to ECs and tumor cells
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randomly divided into four groups for xenograft implant-
ation at the right flank of the fourth inguinal mammary.
The Group 1 mice were injected with IgG-Fc-treated HLE
cells as controls. The Group 2 mice were injected subcuta-
neously with 1× 107 HLE cells stimulated with 5 mg/ml
EphA1-Fc, while the Group 3 and 4 mice were injected
with the same amount of EphA1-Fc-stimulated HLE cells
transfected with SDF-1 specific siRNA (GenPharma,
Shanghai, China) or control scrRNA (GenPharma,
Shanghai, China), respectively. Tumor development
was monitored regularly by observing tumor growth
and measuring the tumor size with a caliper once
every 3 days. At post-xenograft Day 14, all of the mice
were injected with 5 × 105 EPCs through tail veins, at
a time when endogenous tumor angiogenesis was com-
pleted [51]. Prior to injection, the EPCs were co-incubated
with 2 g/mL DiI-ac-LDL (Biomedical Technologies,
Stoughton, Mass) for 1 h. At post-xenograft Day 36, all of
the mice were sacrificed for tumor removal. The tumor vol-
ume was determined using the formula volume =width2 ×
length × 0.52. A portion of the harvested tumor tissue was
fixed in 10 % buffered formalin and embedded in paraffin
for immunohistochemical (IHC) analysis, and the rest was
snap-frozen in liquid nitrogen and stored at −80 °C.
Preparation of conditioned medium (CM-HLE and CM-
Huh-7)
Huh-7 cells transfected with EphA1 siRNA or EphA1
scrRNA were prepared as previously described [20]. To
prepare the transfected HLE cells, after they had grown to
70 %-80 % confluency, the cells were washed three times
with phosphate buffered saline (PBS) and then incubated
in 0.5 % FBS-containing DMEM medium for 48 h. For the
IgG-Fc (R&D, MN, USA) and ephrinA1-Fc (R&D, MN,
USA) activated HLE cell groups, after the cells reached
50–60 % confluency, they were washed three times with
PBS and then incubated in 5 mg/ml IgG-Fc or ephrinA1-
Fc MEM medium containing 0.5 % FBS for 48 h. The cells
were washed three more times with PBS and then
cultured in 0.5 % FBS-containing MEM medium for
another 48 h. For SDF-1 specific siRNA or scramble
siRNA transfection, the ephrinA1-Fc activated HLE cells
were incubated with SDF-1 specific siRNA or scrambled
siRNA (scrRNA) for 6 h and then cultured for another
48 h after the medium was replaced with fresh MEM
medium containing 0.5 % FBS. The conditioned media of
both the transfected HLE and Huh-7 cell cultures were har-
vested and centrifuged at 1000 rpm for 10 min to remove
cell debris. After being filtered through a 0.22-μm filter, the
conditioned media were stored at 4 °C for subsequent use.
Co-culture experiments
After stimulation with 5 mg/ml IgG-Fc or ephrinA1-Fc
for 48 h, the EphA1-negative HLE cells were washed three
times and cultured in 0.5 % FBS-containing medium. The
EPCs were cultured on cell culture inserts with a 0.4-μm
pore size (BD Biosciences, CA, USA) at a density of 1 ×
105 cells/insert in 0.5 % FBS-containing medium. After
24 h of equilibration, the inserts containing the EPCs were
added to the plates, with the pretreated HLE cells in the
lower compartment. The cells were co-cultured for 48 h
to allow the diffusion of the medium components without
cell migration. The EPCs were then collected for immuno-
fluorescence (IF) and western blot (WB) assays. All of the
independent experiments were conducted in triplicate.
RNA extraction and quantitative real-time reverse tran-
scription polymerase chain reaction (RT-PCR) analysis
Total RNA was extracted using the RNAeasy mini kit
(Qiagen, CA, USA). cDNA synthesis was performed using
the High-Capacity cDNA Reverse Transcription kit from
Applied Biosystems (Grand Island, NY, USA) to transcribe
2 μg of total RNA. RT-PCR was used to semi-quantify the
mRNA levels using an ABI 7300 system. The assay was
performed with specific primers at 95 °C for 10 min,
followed by 38 cycles of 95 °C for 15 s and 60 °C for 60 s.
The mRNA level was determined before and after treat-
ment with the comparative ΔΔCt method using 18S ribo-
somal RNA as the normalization gene. The statistical
significance and standard error were determined using the
ΔCt values. All reactions were performed in triplicate. The
primer sequences are listed in Table 1.
Western blot analysis
The siEphA1/Huh-7 cells and scrEphA1/Huh-7 cells were
cultured overnight in DMEM medium containing 0.5 %
FBS. The HLE cells were stimulated with 5 mg/ml
EphrinA1-Fc or 5 mg/ml IgG-Fc in MEM medium
containing 0.5 % FBS for 48 h, with the latter serving as a
negative control. Subsequently, the ephrinA1-Fc-stimulated
HLE cells were treated with 2 ng/ml LY294002 (SIGMA,
MO, USA), a phosphoinositide 3-kinases (P13K)/Akt inhibi-
tor, or 2 ng/ml rapamycin (SIGMA, MO, USA), an mTOR
signaling pathway inhibitor, for 24 h. The cells were then
washed and lysed using lysis buffer. After protein quantifi-
cation with a bicinchoninic acid (BCA) protein assay kit
(Pierce, IL, USA), equal amounts of protein (40 μg/lane)
were separated using 4–15 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
(Millipore, MA, USA). After blocking for 1 h with 5 % BSA
and washing with TBST, the membranes were probed with
polyclonal or monoclonal antibodies against EphA1
(1:1000), EphA2 (1:1000), SDF-1 (1:1000), ERK (1:1000),
phospho-ERK (1:1000), Akt (1:1000), phospho-Ake1:1000),
mTOR(1:1000), phospho-mTOR (1:1000), or β-actin
(1:5000) via incubation at 4°C overnight. Subsequently,
goat anti-mouse or goat anti-rabbit horseradish
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peroxidase (HRP)-conjugated secondary antibodies
(1:10000) were used to detect antigen antibody com-
plexes. Immune complexes were visualized using the
HyGLO HRP detection kit from Denville Scientific
(Metuchen, NJ, USA) and exposed to X-ray films. β-
actin was detected to verify equal loading. Each experi-
ment was repeated at least three times. All antibodies
are listed in Additional file 3: Table S1.
SDF-1 and CXCR4 co-immunoprecipitation (IP)
EPCs collected from the co-culture experiment were
washed twice with ice-cold PBS and lysed via incubation on
ice for 30 min in 1 ml of modified RIPA lysis buffer con-
taining 50 mM Tris–HCl, pH 7.4, 1 % NP-40, 0.25 % Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF,
aprotinin, leupeptin, and pepstatin: 1 μg/ml each,1 mM
Na3VO4, 1 mM NaF, and a commercial protease inhibitor
mixture (Complete-Mini Protease Inhibitor Mixture; Roche
Diagnostics). After the proteins were quantified and the
concentration was adjusted with PBS to approximately
2 μg/μl, the cell lysate was pre-cleared by adding 20 μl of
protein G sepharose bead slurry per ml of cell lysate and in-
cubating at 4 °C for 1 h on a rocker. SDF-1 and CXCR4
proteins were immunoprecipitated by incubating pre-
cleared lysate with rabbit anti-SDF-1 antibody or mouse
anti-CXCR4 antibody and protein G-Sepharose (40 μl)
overnight at 4 °C. The immune complexes were pelleted by
centrifugation for 1 min at 14,000 × g, washed three times
with lysis buffer, and released from the beads by boiling for
5 min in 40 μl 2× sample buffer. The beads were collected
using centrifugation, and the supernatants were resolved
with SDS-PAGE and subjected to WB analysis, as described
in the preceding section.
IHC staining
For IHC staining, the tumor tissues were fixed in forma-
lin, embedded in paraffin, cut into 4-μm sections, and
stained using antibodies against CD31 (1:600). Negative
controls were established by substituting the primary
antibody with 1 % BSA-TBS. To quantify the tumor
microvascular density (MVD), CD31-positive cells were
identified by a brown precipitate in the cytoplasm of the
endothelial cells, and the vessels in each section were
counted in five independent microscope fields [52].
IF staining and confocal microscopy
Sections of HCC cells and tumor tissues were perme-
abilized with 0.1 % Triton X-100 in PBS for 30 min. The
sections were then blocked with 5 % goat serum for 1 h at
room temperature and incubated with anti-CD31 or anti-
SDF-1 overnight at 4 °C. Next, the sections were rinsed in
PBS and incubated for 1 h at room temperature with
Alexa Fluor 488-conjugated anti-mouse and Alexa Fluor
594-conjugated anti-rabbit IgG from Molecular Probes
(Grand Island, NY, USA) and Invitrogen (Carlsbad, CA,
USA), respectively. The sections were mounted with Pro-
long Gold anti-fade reagent with DAPI from Invitrogen
(Carlsbad, CA, USA).
The aforementioned EPCs were seeded on Falcon™
eight-well culture slides. After rinsing with Dulbecco’s
PBS (D-PBS) at room temperature, the cells were fixed
with 2.5 % formaldehyde in PIPES for 20 min. They were
then rinsed with D-PBS and blocked with 5 % normal goat
serum for 1 h at 37°C. After incubation with antibodies
against SDF-1, CXCR4, EphA1, CD31, CD133, CD45,
CD90, VEGFR2, or eNOS for 1 h at 37°C, the cells were
processed IF procedures similar to those described above.
The slides were examined under a confocal microscope
(Zeiss LSM 510, Carl Zeiss Inc., Thornwood, NJ). For the
negative control sections, the primary antibody was re-
placed with PBS.
Enzyme-linked immunosorbent assay (ELISA)
The conditioned media were collected from the siE-
phA1/Huh-7, scrEphA1/Huh-7, and siEphA2/Huh-7,
and scrEphA2/Huh-7 cell cultures and from the HLE
cell culture in which the cells were incubated in low
serum medium (0.5 % FBS) for 48 h after stimulation in
low serum medium (0.5 % FBS) MEM medium contain-
ing 5 mg/ml IgG-Fc or ephrinA1-Fc for 48 h. The SDF-1
concentrations were measured using a human SDF-1
immunoassay kit from Abcam (Cambridge, MA, USA).
Cell chemotaxis assay
The chemotaxis of EPCs to different HCC cell groups was
measured using the Transwell assay according to the fol-
lowing procedures. First, 5 × 104 EPCs in 500 μL of
serum-free medium were seeded in a 24-well chamber
with an 8-μm pore size (BD Biosciences, CA, USA). Sub-
sequently, siEphA1 and scrEphA1-transfected Huh-7 cells
and ephrinA1-Fc- or IgG-Fc- stimulated HLE cells were
seeded in the lower compartment. After 24 h of culturing
at 37 °C, the cells on the upper surface of membrane were
completely wiped away with a cotton swab. The migrated
cells adhering to the lower surface of the membrane were
fixed with 100 % methanol, stained with crystal violet and
counted under a light microscope. The migrated cells
were counted in five randomly selected microscopic fields
for each chamber, and chemotaxis was expressed as the
number of migrated cells per field.
EPCs incorporation assay
EPCs and HUVECs were used for tube formation assays as
described previously [53]. EPCs were labeled with Dil-ac-
LDL (Molecular Probes, 2 ug/mL) at 37 °C for 20 min.
After washing with PBS, 1,000 of the Dil-ac-LDL labeled
EPCs were mixed with 10,000 of HUVECs in 100 uL of
10 % FBS/EGM-2 MV medium (Lonza) in order to evaluate
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the contribution of EPCs to Endothelial Cells derived tube
formation. 100uL of cell suspensions were applied to 50 μL
of Matrigel coated Falcon™ eight-well culture slides and
then incubated for 24 h. After this, cell were fixed, followed
by mounting with Prolong Gold anti-fade DAPI. The slides
were examined and counted under a confocal microscope
(Zeiss LSM 510, Carl Zeiss Inc., Thornwood, NJ).
Cell tube formation assay
First, growth factor-reduced Matrigel (BD Biosciences, San
Jose, CA, USA) was thawed and placed in a precooled 96-
well plate. The plate was then kept at 37 °C for 1 h to allow
the matrix solution to gel. After culturing in conditioned
medium from the 0.5 % FBS-containing siEphA1- or
scrEphA1-transfected Huh-7 cell cultures and ephrinA1-
Fc- or IgG-Fc-stimulated HLE cell cultures for 12 h, the
EPCs were resuspended in the respective conditioned
media at a density of 1 × 105 cells/mL. Subsequently,
100 μL of the cell suspension was loaded onto the surface
of the gelled matrix and incubated at 37 °C for 8 h. The
tubule length was measured using Image J image analysis
software downloaded from the NIH website (Bethesda,
MD, USA). In another set of experiments, the EPCs were
incubated with conditioned media from the HLE cell
cultures that were stimulated with 5 mg/ml ephrinA1-Fc or
IgG-Fc and then transfected with SDF-1-specific siRNA or
control siRNA. Each experiment was performed in
triplicate.
Wound healing assay
Cell migration ability was tested using a wound healing
assay. SiEphA1/Huh-7 cells, scrEphA1/Huh-7 cells and
ephrinA1-Fc- or IgG-Fc-stimulated HLE cells in their cor-
responding 0.5 % FBS-containing medium were seeded at a
density of 1 × 105 cells/well in a six-well plate and incu-
bated until an even monolayer at 90 % confluence was
achieved. Two mechanical scratches were made to create
uniformly sized wounds in all wells. Imaging of the healing
wounds was performed at 0, 24 and 48 h post-scratch. The
percentage of wound closure was calculated for each well,
and the data were normalized to controls.
Statistical analysis
The results are expressed as the means ± standard de-
viation (SD). Multiple comparisons were conducted
using the Student t-test. Statistical significances were
accepted at *p < 0.05 and **p < 0.001.
Additional files
Additional file 1: Figure S1. Identification of EPCs. A. Representative
images of EPCs at the 7th day (top panel) and 21st (bottom panel) day
after separation from peripheral blood. B. EPCs were characterized
according to the presence of endothelial-specific markers, such as CD31,
CD133, eNOS, or VEGFR2, or the absence of mesenchymal-specific
markers, such as CD45 and CD90. Scale bar: 50 μm. C. Representative
images of EPC’s uptake of DiI-ac-LDL and binding of FITC-UEA-1. Scale
bar: 50 μm. D. Representative images showing the capacity of EPCs to
induce tube formation on Matrigel. (JPG 95 kb)
Additional file 2: Figure S2. EphrinA1-Fc increases EphA1 expression in
HLE cells. A. WB assay of EphA1 and EphA2 expressed in HLE cells after
activation with IgG-Fc or ephrinA1-Fc, with β-actin expression as a control
for protein loading. B. IF staining of EphA1 and EphA2 expressed in HLE
cells after activation with IgG-Fc or ephrinA1-Fc. Scale bar: 10 μm. C.
EphA2 knockdown in Huh-7 cells. A. EphA2 mRNA expression in Huh-7
cells after EphA2 knockdown by EphA2 siRNA, determined with RT-PCR.
B. Bar graph shows EphA2 mRNA expression after EphA2 scrRNA (black
bar) and EphA2 siRNA transfection (white bar). The data represent the
mean ± SD of three independent experiments. Asterisks indicate significant
differences (***P < 0.001). D. Huh-7 cells with different EphA2 expression
levels: The result is normalized to the expression in Huh-7 cells transfected
with EphA2 scrRNA for each chemokine. (JPG 154 kb)
Additional file 3: Table S1. List of antibodies used in the study.
(DOCX 15 kb)
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
GC, ZMT and WY designed the experiments. WY, YHT, SYF and TCL carried
out the molecular genetic studies. WF, HJF and GPY carried out the
immunoassays and builded the animal model. YZP, SQT and SHQ performed
the statistical analysis. GC, ZMT and WY drafted the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
The authors are thankful for the financial support from the National Natural
Science Foundation (81201953), the Natural Science Foundation of Zhejiang
Province (Y2090538), the Research Found for the Doctoral Program of High
Education of China from the Ministry of Education (20113321120003)
Author details
1Environmental and Public Health School of Wenzhou Medical University,
Wenzhou 325000, China. 2Department of Hepatobiliary Surgery, The First
Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China.
3Department of Gastroenterology, The First Affiliated Hospital, Wenzhou
Medical University, Wenzhou 325000, China.
Received: 24 December 2015 Accepted: 4 April 2016
References
1. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,
Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research
on Cancer; 2013.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat
Rev Drug Discov. 2007;6(4):273–86.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC,
Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L,
Greten TF, Galle PR, et al. Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008;359(4):378–90.
4. Liang PH, Tian F, Lu Y, Duan B, Stolz DB, Li LY. Vascular endothelial growth
inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial
progenitor cell incorporation into Lewis lung carcinoma tumors.
Angiogenesis. 2011;14(1):61–8.
5. Nguyen MP, Lee D, Lee SH, Lee HE, Lee HY, Lee YM. Deguelin inhibits
vasculogenic function of endothelial progenitor cells in tumor progression and
metastasis via suppression of focal adhesion. Oncotarget. 2015;6(18):16588–600.
6. Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, Kishore R and
Tiwari RK. 17Beta-estradiol mobilizes bone marrow-derived endothelial
progenitor cells to tumors. Cancer Res. 2008;68(15):6038–42.
7. Vajkoczy P, Blum S, Lamparter M, Mailhammer R, Erber R, Engelhardt B,
Vestweber D and Hatzopoulos AK. Multistep nature of microvascular
Wang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:65 Page 13 of 15
recruitment of ex vivo-expanded embryonic endothelial progenitor cells
during tumor angiogenesis. J Exp Med. 2003;197(12):1755–65.
8. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial
progenitor cells control the angiogenic switch in mouse lung metastasis.
Science. 2008;319(5860):195–8.
9. Li CX, Shao Y, Ng KT, Liu XB, Ling CC, Ma YY, Geng W, Fan ST, Lo CM and
Man K. FTY720 suppresses liver tumor metastasis by reducing the
population of circulating endothelial progenitor cells. PLoS One. 2012;7(2),
e32380.
10. Zhu Z, Chen G, Li X, Yin Q, Yang Z, Yi J. Endothelial progenitor cells homing
to the orthotopic implanted liver tumor of nude mice. Journal of Huazhong
University of Science and Technology Medical sciences = Hua zhong ke ji
da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao
Yixue Yingdewen ban. 2012;32(5):675–9.
11. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling
and beyond. Nat Rev Cancer. 2010;10(3):165–80.
12. Zhang J, Hughes S. Role of the ephrin and Eph receptor tyrosine kinase
families in angiogenesis and development of the cardiovascular system. J
Pathol. 2006;208(4):453–61.
13. Foubert P, Silvestre JS, Souttou B, Barateau V, Martin C, Ebrahimian TG, Lere-
Dean C, Contreres JO, Sulpice E, Levy BI, Plouet J, Tobelem G and Le
Ricousse-Roussanne S. PSGL-1-mediated activation of EphB4 increases the
proangiogenic potential of endothelial progenitor cells. J Clin Invest. 2007;
117(6):1527–37.
14. Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R,
Fibbi G, Mazzanti B, Calorini L and Chiarugi P. EphA2-mediated
mesenchymal–amoeboid transition induced by endothelial progenitor cells
enhances metastatic spread due to cancer-associated fibroblasts. J Mol
Med. 2013;91(1):103–15.
15. Wang J, Dong Y, Wang X, Ma H, Sheng Z, Li G, Lu G, Sugimura H and Zhou
X. Expression of EphA1 in gastric carcinomas is associated with metastasis
and survival. Oncol Rep. 2010;24(6):1577–84.
16. Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H and
Kaneko S. Ephrin-A1 expression contributes to the malignant characteristics
of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut. 2005;54(6):
843–51.
17. Fox BP, Tabone CJ, Kandpal RP. Potential clinical relevance of Eph receptors
and ephrin ligands expressed in prostate carcinoma cell lines. Biochem
Biophys Res Commun. 2006;342(4):1263–72.
18. Wang J, Ma J, Dong Y, Shen Z, Ma H, Wang X, Shi S, Wu J, Lu G and Peng L.
High expression of EphA1 in esophageal squamous cell carcinoma is
associated with lymph node metastasis and advanced disease. Apmis. 2013;
121(1):30–7.
19. Maru Y, Hirai H, Takaku F. Overexpression confers an oncogenic potential
upon the eph gene. Oncogene. 1990;5(3):445–7.
20. Chen G, Wang Y, Zhou M, Shi H, Yu Z, Zhu Y and Yu F. EphA1 receptor
silencing by small interfering RNA has antiangiogenic and antitumor
efficacy in hepatocellular carcinoma. Oncol Rep. 2010;23(2):563–70.
21. Hristov M, Weber C. Endothelial progenitor cells: characterization,
pathophysiology, and possible clinical relevance. J Cell Mol Med.
2004;8(4):498–508.
22. Appleby SL, Cockshell MP, Pippal JB, Thompson EJ, Barrett JM, Tooley K, Sen
S, Sun WY, Grose R and Nicholson I. Characterization of a distinct
population of circulating human non-adherent endothelial forming cells
and their recruitment via intercellular adhesion molecule-3. PLoS One. 2012;
7(11):e46996.
23. Foubert P, Squiban C, Holler V, Buard V, Dean C, Levy BI, Benderitter M,
Silvestre JS, Tobelem G and Tamarat R. Strategies to Enhance the Efficiency
of Endothelial Progenitor Cell Therapy by Ephrin B2 Pretreatment and
Coadministration with Smooth Muscle Progenitor Cells on Vascular
Function During the Wound-Healing Process in Irradiated or Nonirradiated
Condition. Cell Transplant. 2015;24(7):1343–61.
24. Funk SD, Yurdagul A Jr., Albert P, Traylor JG Jr., Jin L, Chen J and Orr AW.
EphA2 activation promotes the endothelial cell inflammatory response: a
potential role in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(3):
686–95.
25. Peplow PV. Influence of growth factors and cytokines on angiogenic
function of endothelial progenitor cells: a review of in vitro human studies.
Growth factors (Chur, Switzerland). 2014;32(3–4):83–116.
26. Shih Y-T, Wang M-C, Zhou J, Peng H-H, Lee D-Y, Chiu J-J. Endothelial
progenitors promote hepatocarcinoma intrahepatic metastasis through
monocyte chemotactic protein-1 induction of microRNA-21. Gut. 2015;64(7):
1132-47.
27. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S,
Yuan Y, Wang HY, Cheng SQ, Xie D and Wang XF. TGF-beta-miR-34a-CCL22
signaling-induced Treg cell recruitment promotes venous metastases of HBV-
positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291–303.
28. Ling CC, Ng KT, Shao Y, Geng W, Xiao JW, Liu H, Li CX, Liu XB, Ma YY,
Yeung WH, Qi X, Yu J, Wong N, Zhai Y, Chan SC, Poon RT, et al. Post-
transplant endothelial progenitor cell mobilization via CXCL10/CXCR3
signaling promotes liver tumor growth. J Hepatol. 2014;60(1):103–9.
29. Monnier J, Boissan M, L’Helgoualc’h A, Lacombe M-L, Turlin B, Zucman-Rossi
J, Théret N, Piquet-Pellorce C and Samson M. CXCR7 is up-regulated in
human and murine hepatocellular carcinoma and is specifically expressed
by endothelial cells. Eur J Cancer. 2012;48(1):138–48.
30. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R,
Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK and Duda
DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated
by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid
differentiation antigen-positive myeloid cell infiltration in mice. Hepatology.
2014;59(4):1435–47.
31. Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G,
Zimmermann HW, Vucur M, Huss S, Gassler N, Wasmuth HE, Lira SA, Zender
L, Luedde T, Trautwein C and Tacke F. Adaptive immunity suppresses
formation and progression of diethylnitrosamine-induced liver cancer. Gut.
2012;61(12):1733–43.
32. Gao Q, Zhao Y-J, Wang X-Y, Qiu S-J, Shi Y-H, Sun J, Yi Y, Shi J-Y, Shi G-M
and Ding Z-B. CXCR6 upregulation contributes to a proinflammatory tumor
microenvironment that drives metastasis and poor patient outcomes in
hepatocellular carcinoma. Cancer Res. 2012;72(14):3546–56.
33. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF
and Lai PB. CD133+ liver tumor-initiating cells promote tumor angiogenesis,
growth, and self-renewal through neurotensin/interleukin-8/CXCL1
signaling. Hepatology. 2012;55(3):807–20.
34. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J and
Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and
indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;
56(6):2242–54.
35. Chen K-J, Lin S-Z, Zhou L, Xie H-Y, Zhou W-H, Taki-Eldin A and Zheng S-S.
Selective recruitment of regulatory T cell through CCR6-CCL20 in
hepatocellular carcinoma fosters tumor progression and predicts poor
prognosis. PLoS One. 2011;6(9), e24671.
36. Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY and Kim DG. EFNA1 ligand and
its receptor EphA2: potential biomarkers for hepatocellular carcinoma.
International journal of cancer Journal international du cancer. 2010;126(4):940–9.
37. Melero-Martin JM, Dudley AC. Concise review: Vascular stem cells and
tumor angiogenesis. Stem Cells. 2011;29(2):163–8.
38. Ping YF, Bian XW. Consice review: Contribution of cancer stem cells to
neovascularization. Stem Cells. 2011;29(6):888–94.
39. Salvucci O, de la Luz SM, Martina JA, McCormick PJ, Tosato G. EphB2 and
EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell
chemotaxis and branching remodeling. Blood. 2006;108(9):2914–22.
40. Yamaguchi J-i, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S,
Bosch-Marce M, Masuda H, Losordo DW and Isner JM. Stromal cell–derived
factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment
for ischemic neovascularization. Circulation. 2003;107(9):1322–8.
41. Song T, Dou C, Jia Y, Tu K, Zheng X. TIMP-1 activated carcinoma-associated
fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in
hepatocellular carcinoma. Oncotarget. 2015;6(14):12061–79.
42. Hsu WH, Chen CN, Huang HI, Lai YL, Teng CY, Kuo WH. Urokinase induces
stromal cell-derived factor-1 expression in human hepatocellular carcinoma
cells. J Cell Physiol. 2012;227(2):697–704.
43. Zhu H, Sun Q, Tan C, Xu M, Dai Z, Wang Z, Fan J and Zhou J. Tacrolimus
promotes hepatocellular carcinoma and enhances CXCR4/SDF-1α
expression in vivo. Molecular medicine reports. 2014;10(2):585–92.
44. Isozaki T, Arbab AS, Haas CS, Amin MA, Arendt MD, Koch AE and Ruth JH.
Evidence that CXCL16 is a potent mediator of angiogenesis and is involved
in endothelial progenitor cell chemotaxis: studies in mice with K/BxN
serum–induced arthritis. Arthritis & Rheumatism. 2013;65(7):1736–46.
45. Ishida Y, Kimura A, Kuninaka Y, Inui M, Matsushima K, Mukaida N and Kondo
T. Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial
progenitor cells in mouse wound healing. J Clin Invest. 2012;122(2):711.
Wang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:65 Page 14 of 15
46. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the
MAP/ERK kinase signaling cascade. Oncogene. 2002;21(50):7690–9.
47. Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ. Eph B4
receptor signaling mediates endothelial cell migration and proliferation via the
phosphatidylinositol 3-kinase pathway. J Biol Chem. 2002;277(46):43830–5.
48. Sahin M. Eph receptor and mTOR pathway crosstalk: implications for cancer.
Cell Cycle. 2010;9(11):2053–4.
49. Hjorthaug HS, Aasheim HC. Ephrin-A1 stimulates migration of CD8 + CCR7+
T lymphocytes. Eur J Immunol. 2007;37(8):2326–36.
50. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, Pratt RE, Mulligan
RC and Dzau VJ. Isolation and transplantation of autologous circulating
endothelial cells into denuded vessels and prosthetic grafts implications for
cell-based vascular therapy. Circulation. 2003;108(21):2710–5.
51. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin
Oncol. 2002;29(6 Suppl 16):15–8.
52. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and
metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;
324(1):1–8.
53. Yang J, Ii M, Kamei N, Alev C, Kwon SM, Kawamoto A, Akimaru H, Masuda
H, Sawa Y and Asahara T. CD34+ cells represent highly functional
endothelial progenitor cells in murine bone marrow. PLoS One. 2011;6(5),
e20219.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:65 Page 15 of 15
